Eli Lilly is in a rare position. Its GLP-1 juggernaut — Mounjaro/Zepbound (tirzepatide) — has become one of the most successful launches in modern pharma. Demand is outpacing supply. Revenue is accelerating. The industry is recalibrating around what high-potency incretin therapies can achieve for metabolic disease and longevity. So the obvious question is: Why would…
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
